This site is intended for healthcare professionals only
LoginRegister
Novartis to Acquire Excellergy in USD 2 Billion Deal to Boost Food Allergy PipelineCDSCO Panel Asks Novartis to Submit Revised Protocol, Dose Changes for Ianalumab Phase III Trial
Sanofi DupixentItepekimab met primary endpoint in one of two COPD phase 3 studies: Sanofi, Regeneron
Amazon Only a Platform, Not Seller of Abortion Pills: Court Quashes Notice Against DirectorsASCI Flags 233 Health Ads for DMR Act Violation, Reports to AYUSH Ministry
Strides Pharma Science: Nandini Matiyani joins as Executive VP - Human ResourcesStrides Pharma Science: Senior Vice President - Treasury Ramesh RJ supperannuates
Cipla, Hetero win bid to supply widely prescribed diabetes drug in ChinaDon't throw in the bin, please flush it! CDSCO dictum for these 17 medicines
Delhi HC Bars Dr Reddys from Selling Olymviq Over Similarity with Novo Nordisks OzempicDelhi HC Restrains Dr Reddy's from Selling Semaglutide Drug in India Amid Novo Nordisk Row
AstraZenecas Imfinzi Combo Shows Strong Survival Benefit in Liver Cancer TrialJustify Sample Size Hike in FDC Trial of Zibotentan-Dapagliflozin, CDSCO Panel Tells AstraZeneca
No False Advertising Found: US Court Rejects Bayer Plea to Block Erleada AdsBayer Gets CDSCO Panel Nod To Conduct Phase 3 Trial for Finerenone
MerckMerck, Daiichi Sankyo withdraw US appication for patritumab deruxtecan for advanced or metastatic...
Sun Pharma Seals Rs 97,500 Crore Organon Acquisition DealSun Pharma concludes acquisition of Checkpoint Therapeutics
CiplaUSFDA issues one observation for Cipla Bommasandra facility
Dr. Reddys Labs Bags Health Canada Nod for Ozempic Generic, OneSource to Scale SupplyDr Reddy's Gets SEC Nod for Higher Semaglutide Dose in Ongoing Phase III Study, Govt Sites Mandated
X